Trellus Health. Regulatory News (TRLS)

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION RELATING TO TRELLUS HEALTH PLC AND ITS SECURITIES FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF THE DOMESTIC LAW OF THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("EUWA") AND AS MODIFIED BY OR UNDER THE EUWA OR OTHER DOMESTIC LAW, INCLUDING BUT NOT LIMITED TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR").

Trellus Health plc

("Trellus Health" or the "Company") 

MSA Signed with Leading U.S. Clinical Site Network

and

Funding Update

Trellus Health plc (AIM: TRLS), a healthcare company delivering Trellus Elevate®, a digital platform that integrates data analytics with personalised, scientifically proven resilience programmes and value-based solutions to manage complex chronic conditions, announces that it has signed a master services agreement ("MSA") with Gastro Health ("GH"), a leading clinical trial site network in the United States, to partner and support trial site performance with the use of the TrialSet™ suite of engagement tools, as well as to co-market each other's services.

Whilst the MSA is not immediately revenue-generating, it further validates the strength and differentiation of the Company's TrialSet™ offering in the clinical trial sector and establishes a framework for future commercial opportunities. It also enables each party access to each other's client base through opportunities to co-market. The Company is also progressing advanced late stage discussions regarding an additional clinical trial collaboration and will update the market in due course.

Dr. Marla Dubinsky, CEO and Co-founder of Trellus Health plc said: "This MSA with Gastro Health, alongside the recent extension of our collaboration with J&J and the continued roll-out of TrialSet™ across multiple clinical trials with our CRO partners, further supports the applicability of our platform and proprietary resilience methodology across the pharmaceutical lifecycle, from clinical development through to commercial deployment. We remain focused on disciplined cost management while advancing commercial discussions and converting pipeline opportunities into revenue."

The Company has continued to reduce its monthly cash burn to an average of c. $300k as of March 2026, and expects its cash runway to extend into early April 2026. In addition, the Company is progressing discussions regarding a potential loan from certain Directors and will update the market as appropriate. The Convertible Facility provided by Alumni Capital LLC remains in place, although utilisation is currently constrained by market conditions.

The Board remains supportive of the Company's commercial strategy and is engaged in ongoing discussions regarding a range of potential funding options to further extend the Company's cash runway.

Enquiries:

About Trellus Health plc (www.trellushealth.com)

Trellus Health® (AIM: TRLS) is a healthcare company providing value-based innovative solutions and services, helping people with chronic conditions take control of their health through a proven, scientifically validated self-management solution and continuous, personalised support. Trellus Health's approach empowers patients to better navigate the emotional and physical challenges of their conditions, leading to significant cost savings, enhanced treatment adherence, and long-term, sustainable health outcomes.

Trellus Health® integrates its proprietary resilience-based methodology with the technology, tools, and expert coaching and educator team to deliver Trellus Elevate®, a whole-person technology-enhanced condition management platform. The Company is initially focusing on chronic costly GI conditions that have a high mental health burden, such as Inflammatory Bowel Disease (IBD). Among IBD patients, applying the Trellus Elevate® methodology resulted in over 90% fewer hospitalisations and a reduction of over 70% in emergency room visits. Given the common emotional and mental health struggles associated with a variety of chronic conditions and therapeutic areas, Trellus Health® considers its approach to have potential utility and demand across many conditions.

The Company also offers Trellus TrialSet™, a solution for pharmaceutical partners spanning clinical trials to commercialisation, applying the same validated resilience science and platform to support trial success and long-term patient engagement

The Company was founded by Icahn School of Medicine at Mount Sinai faculty members Marla C. Dubinsky, MD, and Laurie Keefer, PhD, both world-leading experts in treating both the physical and emotional impacts of IBD, with a combined 50 years of pioneering whole-person healthcare innovation.

Shares in Trellus Health were admitted to trading on AIM in May 2021, under the ticker TRLS. For more information, visit: www.trellushealth.com